|
KMID : 1100120230300030209
|
|
대한골대사학회지
2023 Volume.30 No. 3 p.209 ~ p.217
|
|
|
Position Statement: Atypical Femoral Fracture from the Korean Society for Bone and Mineral Research in 2023
|
|
Zabah Jawa
Jang Byung-Woong
Lee Dong-Woo
Kim Jae-Hyun
Lim Tae-Kang
Cha Soo-Min
Seo Dong-Kyo
Park Yong-Geun
Offir Ukashi
Lee Young-Kyun
Ha Yong-Chan
|
|
|
Abstract
|
|
|
|
As the aging population increases, the number of patients with osteoporosis is gradually rising. Osteoporosis is a metabolic bone disease characterized by low bone mass and the microarchitectural deterioration of bone tissue, resulting in reduced bone strength and an increased risk of low-energy or fragility fractures. Thus, the use of anti-resorptive agents, such as bisphosphonates (BPs), to prevent osteoporotic fractures is growing annually. BPs are effective in reducing hip and other fractures. However, the longer a patient takes BPs, the higher the risk of an atypical femoral fracture (AFF). The exact mechanism by which long-term BP use affects the development of AFFs has not yet been clarified. However, several theories have been suggested to explain the pathogenesis of AFFs, such as suppressed bone remodeling, impaired bone healing, altered bone quality, and femoral morphology. The management of AFFs requires both medical and surgical approaches. BPs therapy should be discontinued immediately, and calcium and vitamin D levels should be evaluated and supplemented if insufficient. Teriparatide can be used for AFFs. Intramedullary nailing is the primary treatment for complete AFFs, and prophylactic femoral nailing is recommended if signs of an impending fracture are detected.
|
|
|
KEYWORD
|
|
|
Diphosphonates, Femoral fractures, Femur, Osteoporosis
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|
|
|